Cargando…

Fingolimod treatment promotes regulatory phenotype and function of B cells

OBJECTIVE: To evaluate the influence of Fingolimod treatment on B-cell subset composition and function in multiple sclerosis patients and its potential clinical relevance. METHODS: Subset composition and cytokine production of B cells derived from peripheral blood mononuclear cells from multiple scl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grützke, Berit, Hucke, Stephanie, Gross, Catharina C, Herold, Martin V B, Posevitz-Fejfar, Anita, Wildemann, Brigitte T, Kieseier, Bernd C, Dehmel, Thomas, Wiendl, Heinz, Klotz, Luisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338953/ https://www.ncbi.nlm.nih.gov/pubmed/25750917 http://dx.doi.org/10.1002/acn3.155

Ejemplares similares

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking
por: Posevitz-Fejfár, Anita, et al.
Publicado: (2014)

Liver X receptor activation promotes differentiation of regulatory T cells
por: Herold, Martin, et al.
Publicado: (2017)

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study
por: Lohmann, Lisa, et al.
Publicado: (2018)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling
por: Szepanowski, Fabian, et al.
Publicado: (2016)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells
por: Trinschek, Bettina, et al.
Publicado: (2015)

Novel pathomechanisms in inflammatory neuropathies
por: Schafflick, David, et al.
Publicado: (2017)

Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis
por: Trinschek, Bettina, et al.
Publicado: (2013)

Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis
por: Trinschek, Bettina, et al.
Publicado: (2013)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Phosphoprotein Associated with Glycosphingolipid-Enriched Microdomains Differentially Modulates Src Kinase Activity in Brain Maturation
por: Lindquist, Sabine, et al.
Publicado: (2011)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies
por: Meyer zu Hörste, Gerd, et al.
Publicado: (2014)

The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia
por: Malone, Kyle, et al.
Publicado: (2021)

Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
por: Fleck, Ann-Katrin, et al.
Publicado: (2021)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devices—A Critical Appraisal
por: Wick, Manfred, et al.
Publicado: (2021)

Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
por: Trümpelmann, Susan, et al.
Publicado: (2022)

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
por: Serpero, Laura D., et al.
Publicado: (2013)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Gut–CNS-Axis as Possibility to Modulate Inflammatory Disease Activity—Implications for Multiple Sclerosis
por: Fleck, Ann-Katrin, et al.
Publicado: (2017)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Erythropoietin Ameliorates Rat Experimental Autoimmune Neuritis by Inducing Transforming Growth Factor-Beta in Macrophages
por: Mausberg, Anne K., et al.
Publicado: (2011)

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG Oligonucleotide
por: Smolianov, Vsevolod, et al.
Publicado: (2011)

Interleukin-17 impedes Schwann cell-mediated myelination
por: Stettner, Mark, et al.
Publicado: (2014)

Cytotoxic CD8(+) T cells and CD138(+) plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies
por: Melzer, Nico, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_14ha4jv765d0arjt82p1e6vech